100 related articles for article (PubMed ID: 21456002)
1. A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma.
Kirkwood JM; Gonzalez R; Reintgen D; Clingan PR; McWilliams RR; de Alwis DP; Zimmermann A; Brown MP; Ilaria RL; Millward MJ
Cancer; 2011 Oct; 117(20):4732-9. PubMed ID: 21456002
[TBL] [Abstract][Full Text] [Related]
2. A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.
Hamid O; Ilaria R; Garbe C; Wolter P; Maio M; Hutson TE; Arance A; Lorigan P; Lee J; Hauschild A; Mohr P; Hahka-Kemppinen M; Kaiser C; Turner PK; Conti I; Grob JJ
Cancer; 2014 Jul; 120(13):2016-24. PubMed ID: 24676877
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.
Ryan CW; Matias C; Agulnik M; Lopez-Pousa A; Williams C; de Alwis DP; Kaiser C; Miller MA; Ermisch S; Ilaria R; Keohan ML
Invest New Drugs; 2013 Feb; 31(1):145-51. PubMed ID: 22539091
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors.
Gordon MS; Ilaria R; de Alwis DP; Mendelson DS; McKane S; Wagner MM; Look KY; LoRusso PM
Cancer Chemother Pharmacol; 2013 Jan; 71(1):21-7. PubMed ID: 23228983
[TBL] [Abstract][Full Text] [Related]
5. Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II study.
Scagliotti GV; Ilaria R; Novello S; von Pawel J; Fischer JR; Ermisch S; de Alwis DP; Andrews J; Reck M; Crino L; Eschbach C; Manegold C
J Thorac Oncol; 2012 Jun; 7(6):1053-7. PubMed ID: 22588156
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors.
Simon GR; Ilaria RL; Sovak MA; Williams CC; Haura EB; Cleverly AL; Sykes AK; Wagner MM; de Alwis DP; Slapak CA; Miller MA; Spriggs DR
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1233-41. PubMed ID: 21431416
[TBL] [Abstract][Full Text] [Related]
7. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
Hauschild A; Trefzer U; Garbe C; Kaehler KC; Ugurel S; Kiecker F; Eigentler T; Krissel H; Schott A; Schadendorf D
Melanoma Res; 2008 Aug; 18(4):274-8. PubMed ID: 18626312
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors.
Fujiwara Y; Ando Y; Mukohara T; Kiyota N; Chayahara N; Mitsuma A; Inada-Inoue M; Sawaki M; Ilaria R; Kellie Turner P; Funai J; Maeda K; Minami H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):991-8. PubMed ID: 23370664
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.
Eisen T; Thomas J; Miller WH; Gore M; Wolter P; Kavan P; Martín JA; Lardelli P
Melanoma Res; 2009 Jun; 19(3):185-92. PubMed ID: 19436178
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
Vestermark LW; Larsen S; Lindeløv B; Bastholt L
Acta Oncol; 2008; 47(8):1526-30. PubMed ID: 18607876
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma.
Spitler LE; Boasberg P; O'Day S; Hamid O; Cruickshank S; Mesko S; Weber RW
Am J Clin Oncol; 2015 Feb; 38(1):61-7. PubMed ID: 25616203
[TBL] [Abstract][Full Text] [Related]
13. [Hepatic intra-arterial bio-chemotherapy for the treatment of melanoma patients with liver metastasis: a phase II clinical study].
Cui CL; Chi ZH; Yuan XQ; Lian HY; Si L; Guo J
Ai Zheng; 2008 Aug; 27(8):845-50. PubMed ID: 18710619
[TBL] [Abstract][Full Text] [Related]
14. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma.
O'Day S; Gonzalez R; Lawson D; Weber R; Hutchins L; Anderson C; Haddad J; Kong S; Williams A; Jacobson E
J Clin Oncol; 2009 Nov; 27(32):5452-8. PubMed ID: 19826135
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
16. An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Jotte RM; Von Hoff DD; Braiteh F; Becerra CR; Richards DA; Smith DA; Garbo L; Stephenson J; Conkling PR; Robert-Vizcarrondo F; Chen J; Turner PK; Chow KH; Tai DF; Ilaria R
Invest New Drugs; 2015 Feb; 33(1):148-58. PubMed ID: 25260842
[TBL] [Abstract][Full Text] [Related]
17. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer.
Mantovani G; Macciò A; Mulas C; Massa E; Madeddu C; Mura L; Contu P; Versace R
Oncol Rep; 2002; 9(3):661-70. PubMed ID: 11956647
[TBL] [Abstract][Full Text] [Related]
18. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
Kim KB; Eton O; East MJ; Hodges C; Papadopoulos NE; Grimm EA; Bedikian AY
Cancer; 2004 Aug; 101(3):596-603. PubMed ID: 15274073
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-21 has activity in patients with metastatic melanoma: a phase II study.
Petrella TM; Tozer R; Belanger K; Savage KJ; Wong R; Smylie M; Kamel-Reid S; Tron V; Chen BE; Hunder NN; Hagerman L; Walsh W; Eisenhauer EA
J Clin Oncol; 2012 Sep; 30(27):3396-401. PubMed ID: 22915661
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]